KEMOTERAPİ ÖNCESİ ALINABİLECEK ÖNLEMLER

Kaynaklar:

1-Chiu, L. Chow R., Popovic M., Navari, R.M., Shumway, N. M., Chiu, N., … DeAngelis, C. (2016). Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): A systematic review and meta-analysis. Supportive Care in Cancer, 24 (5), 2381–2392.

2-Chouhan, J. D., Herrington, J. D. (2011). Single premedication dose of dexamethasone 20 mg IV before docetaxel administration. Journal of Oncology Pharmacy Practice, 17 (3), 155–159.

3-Chung, C. H. (2008). Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist, 13 (6), 725–732. 

4-Chung, C. H. Mirakhur, B. Chan, E., Le, Q., Berlin, J., Morse, M.,… Platts-Mills, T. A. (2008). Cetuximab-induced anaphylaxis and IgE-specific for Galactose-α-1,3-Galactose. New England Journal of Medicine, 358 (11), 1109–1117.

5-Clemmons, A. B., Orr J., Andrick B., Gandhi, A., Sportes, C., DeRemer, D. (2018). Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematological malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: The FOND-O Trial. Biology of Blood and Marrow Transplantation, 24 (10), 2065–2071. 

6-Clemons, M. (2018). Guidelines versus individualized care for the management of CINV. Supportive Care in Cancer, 26 (S1), 11–17. 

7- Roeland, E. J. Ruddy, K.J., BeBlanc, T. W., Nipp, R. D., Binder, G., Sebastiani, S Navari, R. M. (2020). What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy. Journal of the National Comprehensive Cancer Network. 18 (6), 676–681.

8- Razvi, Y. Chan, S., McFarlane, T., McKenzie, E., Zaki, P., DeAngelis, C., … Jerzak, K. J. (2019). ASCO, NCCN, MASCC/ESMO: A comparison of antiemetic guidelines for the treatment of chemotherapy induced nausea and vomiting in adult patients. Supportive Care in Cancer, 27, 87–95.

9- National Comprehensive Cancer Network. (2021). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. V1.2021. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf

10- Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., … Engert, A. (1999). Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood, 94 (7), 2217–2224.

11- Barr, H., Dempsey, J., Waller, A., Huang, Y., Williams, N., Sharma, N.Hofmeister, C. C. (2018). Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia, 32 (11), 2495–2518. 

12- O’Cearbhaill, R., Zhou, Q., Iasonos, A., Hensley, M. L., Tew, W. P., Aghajanian, C.,… Sabbatini, P. J. (2010). The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecologic Oncology, 116 (3), 326–331. 

13- Parinyanitikul N., Tanpipattanakul, W., Poovorawan, N., Rattananupong, T., Laoitthi, P., Sithidetphaiboon, P, Sriuranpong, V. (2018). Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy. Supportive Care in Cancer, 26 (7), 2471–2477.

 14-Pellegrino, B., Boggiani, D., Tommasi, C., Palli, D., Musolino, A. (2017). Nab-paclitaxel after docetaxel hypersensitivity reaction: Case report and literature review. Acta Bio-Medica, 88 (3), 329–333.

15-Picard, M.,Castells, M. C. (2014). Re-visiting hypersensitivity reactions to taxanes: A comprehensive review. Clinical Reviews in Allergy & Immunology, 49 (2), 177–191.

16-GH Lyman, DC Dale, E Culakova, et al: The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: A systematic review and meta-analysis of randomized controlled trials Ann Oncol 24: 2475– 2484,2013.

17-GH Lyman, DC Dale, DA Wolff, et al: Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review J Clin Oncol 28: 2914– 2924,2010.

18-NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors National Comprehensive Cancer Network (version 2.2014).

19-CL Bennett, B Djulbegovic, LB Norris, et al: Colony-stimulating factors for febrile neutropenia during cancer therapy N Engl J Med 368: 1131– 1139,2013.

20-E Culakova, R Thota, MS Poniewierski, et al: Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: A nationwide prospective cohort study Cancer Med 3: 434– 444,2014.

21-D Weycker, X Li, J Edelsberg, et al: Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors J Oncol Pract 10: 47– 54,2015.

22-GP Bodey, M Buckley, YS Sathe, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia Ann Intern Med 64: 328– 340,1966.

23-J Crawford, H Ozer, R Stoller, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 325: 164– 170,1991.

24-MS Aapro, J Bohlius, DA Cameron , etal: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47: 8– 32,2011.

25-L Balducci, H Al-Halawani, V Charu, et al: Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim Oncologist 12: 1416– 1424,2007.

26-J Bohlius, C Herbst, M Reiser, et al: Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma Cochrane Database Syst Rev 8: CD003189,2008.

27-KL Cooper, J Madan, S Whyte, etal: Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis BMC Cancer 11: 404,2011.

28-Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–2931.

29-Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–2510.

30-Quinn GP, Vadaparampil ST, Bell-Ellison BA, Gwede CK, Albrecht TL. Patient-physician communication barriers regarding fertility preservation among newly diagnosed cancer patients. Soc Sci Med. 2008;66(3):784–789. 

31-Brougham MF, Wallace WH. Subfertility in children and young people treated for solid and haematological malignancies. Br J Haematol. 2005;131(2):143–155. 

32-Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol. 1992;166(3):788–793. 

33-Chatterjee R, Kottaridis PD. Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies. Bone Marrow Transplant. 2002;30(10):629–635. 

34-Chemes HE. Infancy is not a quiescent period of testicular development. Int J Androl. 2001;24(1):2–7. 

35-Thomson AB, Campbell AJ, Irvine DC, Anderson RA, Kelnar CJ, Wallace WH. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet. 2002;360(9330):361–367. 

36-Green DM, Liu W, Kutteh WH, Ke RW, Shelton KC, Sklar CA, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014;15(11):1215–1223.

37-Agarwal A, Shekarriz M, Sidhu RK, Thomas AJ., Jr Value of clinical diagnosis in predicting the quality of cryopreserved sperm from cancer patients. J Urol. 1996;155(3):934–938.

38- Cairo Mitchell S, Bishop Michael. Tumour lysis syndrome: new therapeutic strategies and classification. British journal of haematology. 2004;127:3–11.

39-Cairo Mitchell S, Coiffier Bertrand, Reiter Alfred, Younes Anas. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. British journal of haematology. 2010;149:578–586.

40-Coiffier Bertrand, Altman Arnold, Pui Ching-Hon, Younes Anas, Cairo Mitchell S. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008;26: 2767–2778.

41-Burghi G, Berrutti D, Manzanares W. [Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare]. Medicina intensiva / Sociedad Española de Medicina Intensiva y Unidades Coronarias. 2011;35: 170–178.